CODEPREX
LOE Approachingchlorpheniramine polistirex; codeine polistirex
NDAORALSUSPENSION, EXTENDED RELEASE
Approved
Jun 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
CODEPREX (chlorpheniramine polistirex; codeine polistirex) is mu-opioid receptor, although it can interact with other opioid receptors at higher doses. First approved in 2004.
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CODEPREX is an extended-release oral suspension combining codeine polistirex (opioid cough suppressant) and chlorpheniramine polistirex (first-generation antihistamine) approved in 2004. It is indicated for cough and upper respiratory symptoms by acting centrally on the cough center while reducing histamine-mediated airway edema. The formulation uses polistirex salt technology for prolonged drug delivery.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), suggesting shrinking team and transition focus toward managed care defense and generic transition planning.
Mechanism of Action
mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The precise mechanism of action of hydrocodone and other opiates is not known; however, hydrocodone is believed to act centrally on the cough center. In excessive doses, hydrocodone will depress respiration.…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CODEPREX offers limited career growth opportunity given its LOE-approaching status and zero linked job openings, but provides valuable experience in mature product defense, generics transition, and managed care negotiation. This role is best suited for professionals seeking to develop expertise in late-lifecycle management and market access strategy rather than launch or growth-stage innovation.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.